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a b s t r a c t 
Reductions in the blood supply produce considerable injury if the duration of ischemia is prolonged. Para- 
doxically, restoration of perfusion to ischemic organs can exacerbate tissue damage and extend the size of 
an evolving infarct. Being highly metabolic organs, the heart and brain are particularly vulnerable to the 
deleterious effects of ischemia / reperfusion (I / R). While the pathogenetic mechanisms contributing to I / R-
induced tissue injury and infarction are multifactorial, the relative importance of each contributing factor 
remains unclear. However, an emerging body of evidence indicates that the generation of reactive oxygen 
species (ROS) by mitochondria plays a critical role in damaging cellular components and initiating cell death. 
In this review, we summarize our current understanding of the mechanisms whereby mitochondrial ROS 
generation occurs in I / R and contributes to myocardial infarction and stroke. In addition, mitochondrial ROS 
have been shown to participate in preconditioning by several pharmacologic agents that target potassium 
channels (e.g., ATP-sensitive potassium (mKATP) channels or large conductance, calcium-activated potas- 
sium (mBKCa) channels) to activate cell survival programs that render tissues and organs more resistant 
to the deleterious effects of I / R. Finally, we review novel therapeutic approaches that selectively target 
mROS production to reduce postischemic tissue injury, which may prove efﬁcacious in limiting myocardial 
dysfunction and infarction and abrogating neurocognitive deﬁcits and neuronal cell death in stroke. 
c © 2014 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license 
( http: // creativecommons.org / licenses / by-nc-nd / 3.0 / ). ntroduction 
Acute coronary artery disease and stroke are the number one 
nd third leading causes, respectively, of death and disability among 
mericans and in most westernized cultures. Ischemia caused by vas- 
ular obstruction in the cerebral circulation is the most common cause 
f stroke, although increased microvascular permeability and intrac- 
rebral hemorrhage can also result in decreased perfusion. If diag- 
osed in a timely manner, signiﬁcant I / R injury can be avoided by 
rompt treatment with thrombolytic agents or by physical removal of 
he obstruction using angioplasty approaches. Neurons or myocytes 
hat are supplied by vessels downstream from the occlusion die from 
rolonged ischemia and comprise the infarcted region of the tissue 
hat is termed the ischemic core. The cells in this region never regain 
unction and are dead prior to therapeutic intervention in the brain or 
rogress irreversibly to death in the case of severe cardiac ischemia. 
f greater clinical interest are cells that die in a delayed manner after 
eperfusion is initiated. This population of neural or myocyte cells 
urrounds the ischemic core and is referred to as the penumbra in * Corresponding author. 
E-mail address: korthuisr@health.missouri.edu (R.J. Korthuis). 
213-2317/ $ - see front matter c © 2014 The Authors. Published by Elsevier B.V. This is an
icenses / by-nc-nd / 3.0 / ). 
ttp://dx.doi.org/10.1016/j.redox.2014.05.006 stroke and area-at-risk in myocardial I / R. These jeopardized cells are 
not fully reliant on blood ﬂow from the occluded artery, with modest 
perfusion maintained by collateral blood vessels that provides resis- 
tance to ischemic damage. Although penumbral neurons or at-risk 
myocytes do not succumb to the initial ischemia-induced cell death, 
they progress to death during reperfusion in a delayed manner that 
resembles apoptosis. The delayed onset of death provides a window 
of opportunity for therapeutic intervention. Recognition of this initial 
penumbral resistance to cell death led to the concept that treatments 
targeting these cells should be initiated prior to or in the ﬁrst hours 
after recanalization of the obstructed vessel. 
While signiﬁcant progress has been made with regard to iden- 
tifying ROS as key mediators of both detrimental and protective 
responses in I / R, therapeutic antioxidant management of I / R syn- 
dromes such as myocardial infarction, stroke, and circulatory arrest 
has proven disappointingly ineffective [ 1 –4 ]. This is most likely due 
to a number of factors including the fact that untargeted application 
of antioxidants may not differentiate between detrimental vs bene- 
ﬁcial ROS generation. However, recent breakthroughs regarding use 
of targeted antioxidant therapies to enhance therapeutic efﬁcacy of 
treatments to ameliorate oxidative stress in I / R injury have rekin- 
dled interest in use of agents that modify oxidative stress in I / R.  open access article under the CC BY-NC-ND license ( http: // creativecommons.org / 
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Fig. 1. Mechanisms contributing to tissue injury in ischemia / reperfusion (I / R). Cel- 
lular hypoxia secondary to ischemia results in decreased ATP production, which in 
turn, disrupts ion pump function, leading to accumulation of Na + , Ca 2 + , and H + , with 
cellular acidiﬁcation further promoted by a shift to anaerobic glycolysis for energy 
production. Activation and upregulated expression of enzymes capable of producing 
reactive oxygen species (ROS) and electron transport chain (ETC) dysfunction are also 
initiated during ischemia. These events set the stage for a burst of ROS generation 
when molecular oxygen is reintroduced to ischemic tissues when the blood supply is 
re-established. ROS-dependent expression of proinﬂammatory stimuli and expression 
of adhesion molecules by endothelial cells and leukocytes precipitates the inﬁltra- 
tion and activation of neutrophils, T cells and monocytes. Phagocytic Nox2 activation 
results the respiratory burst of superoxide production that further magniﬁes the mas- 
sive oxidative stress that directly damages virtually every biomolecule found in cells 
and induces the programmed cell death responses, apoptosis and necroptosis. Postis- 
chemic ROS generation also activates matrix metalloproteinases (MMPs) and other 
proteases that act to cleave proteins and receptors, thereby impairing their function. 
The net impact of these ROS-dependent events is opening of mitochondrial permeabil- 
ity transition pores (MPTPs), which contributes to swelling and lysis of cells. Increases 
in leukocyte stiffness induced by hypoxia and acidosis during ischemia lead to im- 
paction of these cells in capillaries, an effect that is exacerbated by ROS-dependent 
endothelial cell swelling which in turn reduces their diameter when the blood supply 
is re-established. Thus, a nutritive perfusion impairment becomes prominent during 
reperfusion, despite repair of the precipitating ischemic event. In direct contrast to 
these catastrophic effects of ROS generation secondary to events occurring in ischemia 
and early reperfusion, oxidant production also occurs at later stages of reperfusion as 
tissue repair is initiated. However, ROS production occurs at lower levels that allow 
oxidant species to serve as signaling molecules that participate in transcriptional acti- 
vation of growth factors and promote cell proliferation, differentiation and migration. 
The net effect of these processes is tissue and vascular remodeling, including angio- 
genesis. While some of these repair processes help restore organ function, others such 
as tissue ﬁbrosis contribute over time to eventual organ failure. The mechanisms de- 
picted in this ﬁgure emphasize the concept that ROS generation play key roles in all 
three phases of ischemia / reperfusion injury and cell death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Particularly promising developments have arisen with regard to tar-
geted delivery of therapeutic agents to the mitochondria, as a means
to reduce ROS-dependent I / R injury. The aim of this review is to
summarize evidence supporting a role for mitochondrially-derived
ROS in the pathogenesis of I / R injury and for their participation in
the beneﬁcial protective actions of preconditioning. We begin with a
generalized review of the multifactorial pathogenetic mechanisms of
I / R injury, followed by a brief description of mitochondrial sources
of ROS, before moving on to a review of the evidence supporting
a pivotal role for mitochondrial oxidants in heart and brain injury
induced by I / R. We conclude this review with a brief discussion re-
garding the roles for mitochondrial ROS as redox signaling molecules
that underlie metabolic and ﬂow-dependent vasodilation and ﬁnish
with a summary of work implicating mitochondrial oxidant gener-
ation as an essential trigger for activation of cell survival programs
that enhance tolerance to I / R, which again emphasizes the Jekyll and
Hyde nature of mitochondrial ROS production. From this discussion,
it will be apparent that mitochondrial ROS can exert detrimental or
beneﬁcial effects, a double-edged sword that is probably explained
by the type of oxidant, the amount of ROS produced, and the sub-
cellular site of their production in these two vary different situations
(preconditioning vs I / R). 
General Concepts of I / R Injury 
In tissue subjected to ischemia followed by reperfusion (I / R),
pathologic mechanisms are elicited that produce reversible cell in-
jury and dysfunction, which can progress to irreversible damage if
the nature and extent of ischemia is prolonged or if the pathologic
sequelae to reperfusion are of sufﬁcient magnitude (reviewed in [ 5 ]).
This damage is referred to as I / R injury and can be divided into three
phases ( Fig. 1 ). During ischemia (the ﬁrst phase of injury), interruption
of the blood supply to an organ causes a reduction in oxygen and nu-
trient delivery to the affected tissues. This disrupts ATP generation via
oxidative phosphorylation, causing cells to alter their metabolism and
impairs energy-dependent cellular function. Reduced ATP availability
limits ion pumps in cell membranes, resulting in calcium overload,
structural disorganization, and apoptotic, necroptotic, and necrotic
cell death. In addition, ischemia induces conformational changes in
enzymes such as xanthine oxidase and elicits the formation of proin-
ﬂammatory mediators and expression of adhesion molecules that
promote leukocyte / endothelial cell adhesive interactions. These lat-
ter processes do not directly contribute to injury during the ischemic
phase, but rather set the stage for the second stage of I / R injury
(ie, that due to reperfusion), wherein tissue injury is exacerbated
when the blood supply is re-established ( Fig. 1 ). Paradoxically, the
lack of oxygen during ischemia and the replenishment of oxygen dur-
ing reperfusion both contribute to the total injury sustained by tissues
subjected to I / R. The clinical outcome is also determined by a third
phase of ROS production that occurs during post-reperfusion repair
that is characterized by tissue remodeling and adaptation ( Fig. 1 ). 
Increased generation of reactive oxygen species (ROS) has been
suggested as a major contributor to the pathogenetic mechanisms un-
derlying ischemia, reperfusion, and the later post-reperfusion phase
of I / R injury ( Fig. 1 ). As a second paradox, ROS appear to exert both
detrimental and beneﬁcial effects in I / R, causing damage that leads
to neurocognitive defects in stroke and contribute to the expansion
of infarct size as a result of their production during ischemia and
reperfusion while subserving a signaling function to promote ﬁbro-
sis, angiogenesis, and vascular remodeling during the repair phase
( Fig. 1 ). Moreover, ROS signaling promotes the activation of cell sur-
vival programs when the heart or brain (or other organs) are exposed
to preconditioning stimuli (such as short bouts of ischemia, moderate
ethanol ingestion, or a wide variety of pharmacologic agents) prior to
the onset of prolonged I / R. The double-edged sword effects of I / R-
induced ROS generation may be related to species of ROS produced,the amount of oxidants generated, and the subcellular location and
cellular source of their production under a given set of conditions, as
well as at what time during the three phases of responses to I / R they
are formed. 
Reperfusion represents the second phase of I / R injury and pre-
cipitates the generation of ROS that is fueled by the reintroduction
of molecular oxygen to the tissues ( Fig. 1 ). Xanthine oxidase- and
phagocyte NADPH oxidase-derived oxidants can damage virtually ev-
ery biomolecule found in cells and tissues. Although essential for cell
survival, re-establishing the blood supply to ischemic tissues also de-
livers blood-borne formed elements (platelets and leukocytes), which
become activated and establish adhesive interactions with the walls
of postcapillary venules ( Fig. 1 ). Upon transmigration into the tissues,
these activated leukocytes release their cytotoxic arsenal of ROS and
hydrolytic enzymes to exacerbate parenchymal cell injury. ROS in-
duce tissue dysfunction by directly damaging cells via a number of
mechanisms including peroxidation of cell membrane and organelle
lipids, oxidizing DNA, activation of matrix metalloproteinases and
calpains, producing osmotic cell lysis, induction of no-reﬂow, and
causing opening of the mitochondrial permeability transition pore
( Fig. 1 ). ROS may also induce cell dysfunction and death by indirect
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 echanisms by interacting with NO, fatty acids or free iron to form 
eroxynitrite, peroxyl radicals, and hydroxyl radicals, respectively, 
ach of which are capable of producing even more cellular damage 
han superoxide or hydrogen peroxide. Oxygen-derived ROS also act 
o enhance the inﬂammatory response to reperfusion via formation of 
xidant-dependent proinﬂammatory mediators and upregulation of 
ytokine / chemokine and adhesion molecule expression ( Fig. 1 ). Thus, 
hile there is cellular demand for replenishment of oxygen which is 
et by re-establishing the blood supply, the reintroduction of molec- 
lar oxygen to the tissues results in ROS formation that is detrimental 
o the reperfused tissues. The divergent roles of oxygen in the ﬁrst 
wo phases of I / R injury are referred to as the oxygen paradox. 
A second ROS paradox arises in later phases of reperfusion, where 
OS generation affects several tightly regulated processes that pro- 
ote organ repair and survival ( Fig. 1 ). This third phase constitutes 
he reparative phase of I / R injury and involves ROS-dependent gen- 
ration of growth factors that promote angiogenesis, induce prolif- 
ration and differentiation of vascular smooth muscle cells to effect 
ascular remodeling, and promote the activation of matrix metallo- 
roteinases and other factors that contribute to ﬁbrosis, tissue re- 
odeling and formation of scar tissue. Interestingly, hypoxia induces 
ransport of mitochondria to perinuclear regions by a microtubule- 
ependent mechanism, where they increase nuclear ROS levels to 
nhance the expression of VEGF, a growth factor important in angio- 
enesis [ 6 ]. 
Cells are equipped with a wide variety of oxidant-producing 
nzymes including xanthine oxidase, NADPH oxidases (Nox), and 
yclooxygenases / lipoxygenases. The mitochondria also produce ROS 
rom respiratory chain components, as well as by activation of mi- 
ochondrially localized monoamine oxidase, the growth factor adap- 
or Shc (p66 Shc ), cytochrome b5 reductase, dihydroorotate dehydro- 
enase, mitochondrial ATP-sensitive potassium (mKATP) and large- 
onductance, calcium activated potassium (BKCa) channels, and the 
ox isoform designated Nox4. Superoxide normally produced in mi- 
ochondria is scavenged by manganese-superoxide dismutase (Mn- 
OD or SOD-2) localized in the matrix. In addition, copper / zinc-SOD 
Cu / ZN-SOD or SOD-1), which is typically considered a cytoplasmic 
soform, is also located in mitochondria between its inner and outer 
embranes. These SODs dismutate superoxide to less reactive hydro- 
en peroxide, which can be further metabolized to water and oxygen 
y the catalytic activity of catalase and glutathione peroxidase. Mi- 
ochondrial uncoupling proteins also serve to reduce the production 
f ROS by causing mitochondrial depolarization, which reduces the 
otential driving electron transfer and by allowing protons to reenter 
he matrix, thereby bypassing ATP synthase. 
Mitochondria play a central role in the development of reperfusion 
njury because the recovery of pH, oxidative stress, and calcium over- 
oad induce abrupt opening of mitochondria permeability transition 
ores (mPTPs), high conductance megachannels that are localized to 
ontact sites between the inner and outer mitochondrial membranes 
 7 ]. When opened, mPTPs permit communication between the cyto- 
lasm and the mitochondrial matrix. While low pH during ischemia 
revents opening of the megachannel, oxidative opening of the mPTP 
s critical to reperfusion injury ( Fig. 1 ). Depending on a complex bal- 
nce among cellular inducers and antagonists, the open probability 
f the mPTP can be transient or long-lived. Short-term opening is in- 
olved in cardioprotection that involves transient ROS formation (see 
elow). In contrast, long-lasting mPTP opening, which is facilitated by 
estoration of pH, calcium overload and the burst of ROS formation at 
he onset of reperfusion, is followed by profound and irreversible al- 
erations in cellular bioenergetics. Sustained pore formation results in 
ncreased mitochondrial permeability to ions and other solutes up to 
olecular weights of 1.5 kD and collapse of the mitochondrial mem- 
rane potential. This is rapidly followed by ATP and NAD + depletion, 
elease of accumulated mitochondrial calcium, matrix swelling and 
uter mitochondrial membrane rupture, which in turn results in loss of pyridine nucleotides, release of pro-apoptotic factors, and further 
inhibits electron ﬂow through the electron transport chain. The mas- 
sive release of ROS during reperfusion requires the involvement of 
the mPTP in a ROS-induced ROS release positive feedback loop [ 8 ]. 
It is widely believed that mPTP is thus a major causative event in 
reperfusion injury and cell death. This concept is consistent with the 
observation that cardioprotective interventions all seem to intersect 
at inhibition of the mPTP as an end-effector of enhanced tolerance to 
I / R. 
Mitochondrial sources of ROS 
Mitochondria are the main source of cellular ROS [ 9 ] and contain 
a number of enzymes that convert molecular oxygen to superox- 
ide or its derivative hydrogen peroxide (H 2 O 2 ) ( Fig. 2 ). However, the 
mitochondrial electron transport chain in the inner membrane, also 
known as the respiratory chain, is the most important source of the 
intracellular ROS production. Indeed, it has been estimated that 95% 
of ROS generated in normal (i.e., non-ischemic) cells are derived from 
electron leak from the respiratory chain enzyme complexes [ 10 ]. The 
proton motive force represents the potential energy driving proton 
movement into the mitochondrial matrix for ATP synthesis. It de- 
scribes an electrochemical gradient that consists of a mitochondrial 
membrane potential and a proton gradient, which represent sources 
for mitochondrial ROS generation via electron transfer to oxygen. For 
an extensive and excellent discussion of factors involved in super- 
oxide formation by the complexes comprising the electron transport 
chain, the reader is directed to a recent review of this topic by Chen 
and Zweier [ 11 ]. Importantly, the electron transport chain proteins 
are rich in iron sulfur clusters and heme groups, providing cofactors 
necessary to form highly reactive hydroxyl radicals from hydrogen 
peroxide [ 12 ]. 
Most oxygen consumed by aerobic eukaryotic cells is reduced to 
water through 4 steps of single electron reduction by the terminal cy- 
tochrome c oxidase of mitochondrial respiratory chain. A small pro- 
portion (0.1–2%) of consumed oxygen can also be reduced partially by 
one or two electrons in the mid-pathway of respiratory chain to gen- 
erate superoxide or H 2 O 2 as normal metabolic products of oxygen 
during respiration [ 13 , 14 ]. Superoxide is generated mainly in com- 
plexes I and III [ 15 , 16 ] ( Fig. 2 ). Ubisemiquinone at the Qo site of Q
cycle in complex III appears to be a major site of superoxide produc- 
tion [ 17 , 18 ]. Although electron leak also occurs at complex I of the 
respiratory chain, the precise generating site(s) for superoxide forma- 
tion within this supercomplex has not been established [ 12 , 13 , 19 ]. 
In addition to complexes I and III of the electron transport chain, 
other mitochondrial components are likely to contribute to ROS gen- 
eration, such as growth factor adaptor Shc (p66 Shc ), nicotinamide ade- 
nine dinucleotide phosphate (NADPH) oxidase-4 (Nox4), monoamine 
oxidase (MAO), mitochondrial BKCa and mK ATP channels, cytochrome 
b 5 reductase, and dihydroorotate dehydrogenase ( Fig. 2 ). However, 
the contribution of these enzymes to total mitochondrial ROS pro- 
duction is signiﬁcantly lower than that of the respiratory chain in the 
inner mitochondrial membrane [ 20 ]. 
Recent studies have suggested a novel pathway of mitochondrial 
ROS production and oxidant-induced apoptosis involving that the 66- 
kDa isoform of the growth factor adaptor protein, Shc (p66 Shc ) [ 21 , 22 ] 
( Fig. 2 ). Several chronic stimuli have been shown to activate protein 
kinase C βII (PKC βII) isoform to induce Ser-36 phosphorylation of 
p66 Shc , allowing transfer of the adaptor protein from the cytosol to 
the mitochondrial intermembrane space [ 23 , 24 ]. Once translocated, 
p66 Shc uses reducing equivalents from the electron transport chain 
through the oxidation of cytochrome c to make H 2 O 2 directly with- 
out formation of superoxide. Redox-defective mutants of p66 Shc are 
unable to induce mitochondrial ROS generation and swelling in vitro 
or to mediate mitochondrial apoptosis in vivo [ 21 , 25 , 26 ]. 
Nox enzymes generate ROS as the product of their natural catalytic 
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Fig. 2. Sources of reactive oxygen species (ROS) in mitochondria. The activity of the 
electron transport chain generates a relatively small ﬂux of ROS under normal condi- 
tions, but its production can be greatly magniﬁed by events occurring during ischemia 
and reperfusion. Complex I (NADH dehydrogenase) and complex III (coenzyme Q (CoQ) 
and cytochrome C oxidoreductase) produce superoxide (O 2 
−), which leads to hydrogen 
peroxide (H 2 O 2 ) formation by spontaneous dismutation or via the enzymatic action 
of manganese superoxide dismutase (MnSOD). In the presence of transition metals, 
H 2 O 2 can form the highly reactive hydroxyl radical (OH 
•) superoxide can also inter- 
act with nitric oxide (NO) to form reactive nitrogen oxide species such as peroxyni- 
trite (ONOO −), which produce cellular dysfunction by S-nitrosylating proteins. ROS 
generated by complex I are released into the mitochondrial matrix, while superoxide 
produced by complex III can occur in both the mitochondrial matrix and the intermem- 
brane space between the outer and inner mitochondrial membranes. Other sources of 
mitochondrial superoxide are enzymes glycerol-3-phosphate dehydrogenase (G3PD), 
the growth factor adaptor p66Shc, and NADPH oxidase-4 (Nox4). β-oxidation of fatty 
acids can also result in mitochondrial superoxide generation secondary to oxidation of 
electron transferring protein (ETF) by the catalytic activity of the electron transferring 
ﬂavoprotein ubiquinone oxidoreductase (ETF-QOR), another enzyme expressed on the 
mitochondrial inner membrane. Monoamine oxidase (MAO), which is localized to the 
outer mitochondrial membrane, catalyzes the formation of H 2 O 2 secondary to cate- 
cholamine metabolism. Not depicted are the mitochondrial enzymes aconitase and 
dihydroorotate, which can produce superoxide, but their role in ischemia / reperfusion 
is uncertain.The mitochondrial anion carrier, uncoupling protein-2 (UCP2), functions 
to separate oxidative phosphorylation from ATP synthesis with energy dissipated as 
heat, a phenomenon referred to as the mitochondrial proton leak. UCP2 acts to facilitate 
the transfer of anions from the inner to the outer mitochondrial membrane and the 
return transfer of protons from the outer to the inner mitochondrial membrane. They 
also reduce the mitochondrial membrane potential in mammalian cells. Although it 
was originally thought to play a role in nonshivering thermogenesis, obesity, diabetes 
and atherosclerosis, it now appears that the main function of UCP2 is the control of 
mitochondria-derived ROS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 cycle. When fully assembled, they are the membrane-bound proteins
catalyzing electron transfer from NAD(P)H to oxygen, thus producing
superoxide [ 27 ]. Nox4 is the most ubiquitous of these oxidases outside
of phagocytic leukocytes (which use the Nox2 isoform to generate
ROS in the respiratory burst) and is a major source of ROS in many
cell types, but its role in physiologic signaling and pathologic states is
perhaps the most controversial ( Fig. 2 ). This Nox isoform is localized
to the outer mitochondrial membrane, and like p66Shc, it produces
H 2 O 2 [ 28 , 29 ]. As has been recently reviewed, Nox4 may function to
control the redox set-point and thus inﬂuence cellular metabolism.
This Nox isoform has also been shown to play important roles in cell
differentiation, migration, growth, apoptosis, and senescence, as well
as participating in proinﬂammatory responses and oxygen sensing
[ 30 ]. 
MAO is another prominent source of mitochondrial ROS. This en-
zyme is localized to the outer mitochondrial membrane, where it is
involved in the oxidative breakdown of key neurotransmitters (cat-
echolamines) and generates H 2 O 2 [ 31 ] ( Fig. 2 ). MAO plays the ma-
jor role in the development of oxidative stress of the nervous sys-
tem and heart. When the heart is subjected to chronic neurohumoral
and / or peripheral hemodynamic stress, the attendant abundance of
circulating / tissue monoamines fuels MAO-derived H 2 O 2 production
and has been shown to play in I / R injury [ 26 , 32 , 33 ]. Recent resultsdemonstrate that MAO is an important determinant of redox balance
in human atrial myocardium as well [ 34 ]. 
Mitochondrial ROS and the pathogenesis of I / R 
Overproduction of ROS by mitochondria plays a role in
the pathogenesis of myocardial I / R and stroke via im-
paired endothelium-dependent vasodilator mechanisms, disrupted
excitation–contraction coupling, generation of arrhythmias, direct
damage to biomolecules that result in necrosis, necroptosis and apop-
tosis, induction of mitochondrial permeability transition, and contri-
butions to cardiac ﬁbrosis, remodeling and hypertrophy ( Figs. 1 and
3 ). Overexuberant liberation of ROS secondary to enhanced electron
leak at complexes I and III are major oxidant sources in I / R [ 9 , 35 –
38 ]. Both ischemia- and reperfusion-induced defects in the electron
transport chain leads to increased ROS production in both subsar-
colemmal and interﬁbrillary mitochondria of the heart [ 39 , 40 ]. This
appears to be mediated by oxidant-induced disruption of cardiolipin-
respiratory chain superassemblies in complexes I −III, which further
increases electron leakage fueling superoxide generation [ 9 , 36 , 41 –
45 ] ( Figs. 2 and 3 ). This is exacerbated by peroxynitrite-mediated
protein nitration of complexes I and III at speciﬁc sites [ 9 , 43 , 44 ]. ROS
leakage from the electron transport chain can also activate a mito-
chondrial anion channel (IMAC) that releases ROS into the cytoplasm
and simultaneously contributes to mitochondrial permeability tran-
sition [ 46 , 47 ]. Aquaporin-8 is expressed on the inner mitochondrial
membrane in hepatic (and perhaps other) cells, where it also acts to
facilitate the diffusional transport of H 2 O 2 [ 48 ]. 
In addition to complexes I and III, insufﬁcient oxygen delivery dur-
ing ischemia results in increased electron leakage that is mediated by
hypoxia- and β1 -adrenergic-mediated, mitochondrial protein kinase
A / cAMP-dependent reduction in the activity of complex IV of the
electron transport chain, which can interact with residual oxygen to
produce superoxide [ 9 , 11 , 49 , 50 ]. Owing to the signiﬁcant depletion
of ADP during early reperfusion, the reintroduction of molecular oxy-
gen greatly enhances electron leakage thereby markedly increasing
ROS production that overwhelms oxidant scavenging capacity, per-
oxidizes membrane lipid components, damages mitochondrial DNA,
and inactivates electron transport chain proteins, effects that are
markedly reduced by treatment with a free radical spin trap prior
to ischemia [ 51 ]. Overproduction of ROS via the electron transport
chain and other sources establishes a vicious positive feedback loop
that induces mitochondrial permeability transition and ROS-induced
ROS production [ 8 , 52 , 53 ]. 
Global and focal cerebral ischemia induce different modes of cell
death. Brief periods of global cerebral ischemia cause delayed neu-
ronal cell death by apoptosis. In contrast, most cells in the ischemic
core die by necrosis after focal cerebral ischemia, while cell death in
the ischemic penumbral region occurs by mechanisms dependent on
activation of apoptotic signaling. Like cardiac myocytes, neurons are
long-lived cells that are highly dependent upon oxidative metabolism.
As a consequence, neural tissue is predisposed to cumulative injury
by endogenously produced ROS, even under non-pathological condi-
tions, as evidenced by progressive accumulation of lipofuscin gran-
ules, a pigment composed of a mixture of proteins and lipid oxi-
dation products, in neuronal lysosomes as we age [ 54 ]. Moreover,
long term treatment with dinitrophenol, administered at a dose that
produces mild mitochondrial uncoupling, has been shown to reduce
brain markers of accumulated oxidative stress and increase survival
times [ 55 ]. 
Following induction of focal stroke, cell death in the ischemic
penumbral region becomes evident between 24 and 72 h after reper-
fusion is initiated. During reperfusion, mitochondria (and other oxi-
dant producing enzyme systems) use oxygen as a substrate to gen-
erate ROS, resulting in an immediate increase of multiple markers
of oxidative damage, which then remain elevated for several days
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Fig. 3. Generation of reactive oxygen species (ROS) by mitochondria (mitoROS) is a 
nexus for both activation of cell survival programs that mediate the effect of condition- 
ing stimuli to enhance tolerance to ischemia / reperfusion (I / R) and serves as a focal 
point for overexuberant ROS-induced ROS release that contributes to the pathogene- 
sis of cell injury in I / R. On the one hand, ROS triggers the activation of cell survival 
programs in responses to a number of mildly noxious stimuli such as short bouts of 
ischemia or antecedent ethanol exposure or pharmacologic agents (ethanol or activa- 
tors of mitochondrial ATP-sensitive potassium (mK ATP ) or large conductance, calcium- 
activated potassium (BKCa) channels). The enhanced tolerance to ischemia invoked by 
these mitoROS-dependent conditioning stimuli,which canbe delivered before (precon- 
ditioning), during (preconditioning) or at the onset of reperfusion (postconditioning), 
activate protective protein kinases such as PKC , the expression of prosurvival genes 
(e.g., heme oxygenase-1) and mitochondrial antioxidant defenses (e.g., MnSOD, alde- 
hyde dehydrogenase-1 or ALDH2), as well as targeting the mitochondrial permeability 
transition pore (MPTP) to maintain the channel in a closed state. On the other hand, 
overexuberant ROS generation at the onset of reperfusion, driven by ROS-induced ROS 
release that is fueled by electron transport chain dysfunction, especially at complexes 
I and III, and enhanced activities of p66Shc, monoamine oxidase (MAO), and NADPH 
oxidase-4 (Nox4) in mitochondria, causes the MPTP to open, leading to swelling, cell 
disruption and death. Not depicted is the effect of oxidants to alter the balance of 
mitochondrial ﬁssion and fusion in conditioning and I / R, which emerging evidence 
has implicated as contributory to both processes. The dual nature of ROS as protective 
vs damaging species relates to the type of ROS generated in particular circumstances, 
their concentration, and / or compartmental localization of their production. 
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n 56 ]. More deﬁnitive support for the importance of ROS generation 
n penumbral cell death is derived from studies demonstrating that 
ntioxidant treatment ameliorates cell injury and death in animal 
odels of stroke [ 57 –61 ]. In addition to well-established roles for 
hagocytic NADPH oxidases, NOS, and cyclooxygenase / lipoxygenase 
athways for ROS / RNOS generation in cerebral I / R injury, a growing 
ody of evidence supports formation of mitochondrial oxidants as 
nother contributing factor in neuronal cell death in stroke. For ex- 
mple, ROS generation is enhanced in mitochondria after cerebral I / R 
nd occurs at time points prior to overt neuronal death [ 56 , 62 –64 ]. 
ostischemic impaired function of respiratory chain complexes I −IV 
nd ATP synthase is a likely major cause of enhanced mitochondrial 
OS production in stroke [ 65 , 66 ]. Increased calcium concentrations 
n the mitochondrial matrix induce oxidative stress that contributes 
o the MPT in brain mitochondria exposed to hypoxia / reoxygenation 
nd high calcium [ 67 ]. Moreover, high calcium exposure, as occurs in 
 / R, reversibly inhibits the elimination of hydrogen peroxide in brain 
itochondria [ 68 ]. 
In addition to the respiratory chain complexes, it also appears 
hat NADPH oxidases (Nox) represent important oxidant sources in 
ostischemic tissues ( Figs. 2 and 3 ). Pharmacologic Nox inhibition 
revents glial cell activation, neuronal cell degeneration, and behav- 
oral deﬁcits induced by experimentally-induced cerebral I / R and re- 
uces myocardial infarct size, effects most often attributed to phago- 
ytic Nox2 [ 69 ]. Reductions in ventricular dysfunction, cardiac re- 
odeling, blood–brain-barrier disruption, lipid peroxidation, protein 
itration, and oxidative DNA damage after I / R have been reported in mice deﬁcient in Nox2 or p47phox expression after exposure to 
cerebral I / R [ 70 –78 ]. Similar ﬁndings have been reported for non- 
selective Nox inhibitors, apocynin and diphenyliodonium, in adult 
brain. On the other hand, inhibition of Nox activity fails to prevent 
perinatal brain injury in newborn animals [ 79 ]. Inhibitor studies us- 
ing apocynin and / or diphenyliodonium should be interpreted with 
caution because the former exhibits antioxidant properties while the 
latter is a general ﬂavoprotein inhibitor [ 80 –84 ]. However, use of a 
more selective general Nox inhibitor, VAS2870, administered at 2 and 
12 hours after restoration of cerebral blood ﬂow, decreased infarct 
size, edema, ROS levels, tissue nitration, and apoptosis in wild-type 
mice subjected to middle cerebral artery occlusion and reperfusion 
[ 85 ]. On the other hand, more recent work has shown that this agent 
produces signiﬁcant off-target effects as well, such as thiol alkylation, 
thereby modifying thiol redox status [ 86 ]. 
Mitochondrial Nox4 may also participate in stroke, with some ev- 
idence supporting a pre-eminent role for this isoform ( Figs. 2 and 3 ). 
This is in part related to the fact that Nox4 is the most abundantly 
expressed isoform in the brain and is found in endothelial cells and 
vascular smooth muscle cells, with particularly prominent expres- 
sion and activity exhibited by these cells in the cerebral vasculature 
that varies by gender [ 87 –90 ]. This isoform is unique among the Nox 
family in that it only interacts with p22phox, is constitutively active 
but can be further activated by angiotensin II, TNF- α, certain growth 
factors and the binding protein PolDip2, and produces hydrogen per- 
oxide as its major product [ 91 ]. Since angiotensin II and TNF α are 
expressed during I / R, it is likely that these proinﬂammatory stim- 
uli participate in upregulating Nox4 activity during I / R. In addition, 
siRNA-mediated downregulation of HIF-1 α expression limits the ef- 
fect of hypoxia to increase Nox4 mRNA while HIF1a overexpression 
increases Nox4 mRNA and protein levels, observations which suggest 
that hypoxia should increase Nox4. Indeed, the rapid stabilization and 
activation of HIFs under conditions of low oxygen may be the primary 
initiating event for the upregulation on Nox4 and other isoforms in is- 
chemia, which is augmented by proinﬂammatory signaling molecules 
described above. Importantly, Nox4 appears to be localized in mito- 
chondria (as well as the plasma membrane, endoplasmic reticulum, 
and nucleus) [ 92 ], and as such could represent an important source 
of mitochondrial ROS in I / R. 
More direct support for a role for the Nox4 isoform in stroke 
is provided by the observation that Nox4 mRNA is upregulated in 
stroke models. Importantly, Nox4 knockout mice demonstrated the 
same reductions in injury as VAS2870-treated wild-type mice, and 
the degree of protection afforded by Nox4 deﬁciency was not aug- 
mented by VAS2870 treatment. Taken together, these latter observa- 
tions strongly support the notion that Nox4 is a major contributor to 
the reperfusion component of cerebral I / R injury. In addition to this 
evidence, recent work indicates that Nox4 overexpression speciﬁcally 
in endothelium exacerbates stroke-induced infarct size by a mecha- 
nism that involves Nox4-dependent suppression of eNOS [ 93 ]. On 
the other hand, infarct size was smaller in endothelial-speciﬁc Nox4- 
deﬁcient mice compared to wild-type animals [ 76 ]. As noted above, 
Nox4 is expressed not only in mitochondria, but also in the plasma 
membrane, endoplasmic reticulum, and nucleus) [ 92 ]. Thus, any or 
all of these organelles may be a source of Nox4-derived ROS in I / R, 
not just mitochondria. 
There is evidence suggesting that Nox4-derived oxidants may also 
play a role in the repair processes that arise days after reperfusion is 
established following cerebral ischemia. This notion is based on the 
observation that ROS derived from Nox4 are key signaling molecules 
mediating cell proliferation and differentiation [ 94 –98 ]. For example, 
siRNA knockdown of Nox4 inhibits tube formation and wound healing 
responses in cultured endothelial cells and limits cell migration and 
proliferation induced by VEGF [ 99 , 100 ]. Thus, activation of Nox4 dur- 
ing latter stages of reperfusion may promote angiogenesis to facilitate 
perfusion of previously ischemic tissues. Moreover, Nox4 activity may 
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 inﬂuence vascular smooth muscle differentiation and proliferation in
response to hypoxia [ 101 , 102 ]. Because Nox4-dependent ROS produc-
tion stimulates proliferation and differentiation of cardiac ﬁbroblasts
into myoﬁbroblasts, which may lead to ﬁbrosis, cardiac remodeling
and heart failure, activation of this Nox isoform may not be entirely
beneﬁcial in the setting of recovery in myocardial I / R [ 97 , 103 , 104 ].
Thus, while Nox4-derived ROS are important for postischemic angio-
genesis, these oxidants may also be detrimental owing to effects to
promote hypertrophy or dilatation of the ventricles. These divergent
effects probably arise as a result of site and / or amount of their produc-
tion. Since the effects of Nox4 deﬁciency vs overexpression, induced
during the recovery phase of reperfusion, have not been evaluated in
postischemic heart and brain, it is unclear whether this mitochondrial
oxidant source contributes in beneﬁcial or detrimental ways. Clearly,
much additional work will be required to address this important and
intriguing question and will likely require site-speciﬁc ablation or
overexpression studies. 
Interplay between different ROS sources also appears to play a role
in I / R [ 95 , 105 , 106 ]. Nox-dependent ROS production can trigger mi-
tochondrial dysfunction which in turn provokes oxidant production.
The converse is also true, mitochondrial ROS production can activate
NADPH oxidases [ 8 , 106 , 107 ]. Thus, mitochondrial ROS-induced ROS
release synergistically increases postischemic oxidative stress. The
generation of ROS by mitochondria also demonstrates spatial hetero-
geneity within the organelle and among mitochondria in a cell [ 108 ].
Following oxidative insult, as occurs in I / R, ROS generation preferen-
tially localizes in mitochondrial regions that progress to swelling and
eventually rupture. In addition, fatal oxidative insults result in mas-
sive augmentation of ROS formation in nearly all mitochondria in the
affected cell. However, mild oxidative stress, as might occur with pre-
conditioning stimuli, induces a more heterogeneous ROS formation
that is limited to small numbers of mitochondria [ 108 ], consistent
with the signaling function of compartmentalized elements of the
cell survival program that is activated by these stimuli. 
Excessive ROS formation during reperfusion facilitates opening of
the mPTP which in turn favors ROS formation by inhibiting the res-
piratory chain secondary to mPTP-induced loss of cytochrome C and
pyridine nucleotides [ 109 ]. Mitochondrial DNA is also particularly
vulnerable to the deleterious effects of ROS-induced ROS release dur-
ing reperfusion owing to the lack of protection of mitochondrial DNA
by histones, limited capacity of DNA repair mechanisms, and proxim-
ity to the production site for ROS-induced ROS. Thus, I / R-induced ROS
production induces mitochondrial DNA rearrangement and fragmen-
tation followed by disruption of mitochondrial structure, function,
and eventual lysis. 
The susceptibility of mitochondrial DNA to oxidative modiﬁca-
tion in circulating leukocytes is of considerable potential interest as
this may provide a reliable marker of mitochondrial dysfunction that
could be exploited as a diagnostic indicator for I / R. Oxidative inacti-
vation of mitochondrial aconitase, which predisposes the enzyme to
produce hydroxyl radicals and thus contribute to I / R injury, suggests
that disrupted activity of this enzyme could also be used as a marker
for myocardial infarction. Oxidants generated by mitochondria (and
other sources) interact with NO to produce peroxynitrite and other
reactive nitrogen species which in turn contribute to the formation
of nitrotyrosine residues on proteins, which not only contribute to
cell dysfunction by disrupting protein function, but also serve as a
surrogate marker for oxidative stress. 
Mitochondrially-directed antioxidants reduce I / R injury 
Discovery of the important roles for mitochondrial ROS generation
in the pathogenesis of I / R injury fueled an intense interest in devel-
opment of pharmacologic agents and other therapeutic approaches
that speciﬁcally target the mitochondria and effectively reduce postis-
chemic tissue and organ damage [ 40 , 108 , 110 –121 ]. Treatment withmitoquinone (MitoQ) or mito-phenyl tert-butylnitrone (Mito-PBN),
which contain the antioxidants coenzyme Q (quinone) or PBN, re-
spectively, attached to a lipophilic triphenylphosphonium cation that
allows these derivatives to accumulate in mitochondria owing to its
negative Ψm , limits postischemic inﬂammation and injury. Mimet-
ics of Mn-SOD target mitochondria to inhibit ROS-dependent dam-
age and apoptosis. A series of NO-based and vitamin E molecules,
which are linked to the triphenylphosphonium mitochondrial tar-
geting moiety, have been developed to actively sequester these an-
tioxidants in mitochondria and exert cardioprotection in I / R models.
A more recent focus for protection is aldehyde dehydrogenase-2, a
mitochondrial enzyme that detoxiﬁes aldehydes that have been im-
plicated in myocardial I / R. A small molecule activator of this enzyme,
Alda1, has been shown to reduce postischemic injury. Gene therapy
approaches that target upregulation of mitochondrial antioxidant en-
zymes such as Mn −SOD or matrix peroxiredoxins or overexpressing
pro-survival molecules such as aldehyde dehydrogenase-2 (in addi-
tion to other extramitochondrial targets) hold particular promise as
novel approaches to render cells, tissues and organs resistant to the
deleterious effects of I / R as does use of microRNAs to modulate mi-
tochondrial redox status in postischemic tissues [ 122 , 123 ]. 
Mitochondrial ROS as signaling molecules: preconditioning and 
cell survival in I / R 
While excess mitochondrial oxidant generation is well known to
exert detrimental effects via mitochondrial dysfunction and ener-
getic decline, a growing body of recent evidence has established that
generation of ROS at low levels by this organelle can serve as sig-
nals mediating physiologic responses. For example, acetylcholine and
ﬂow-induced coronary vasodilation is mediated by activation of BKCa
channels that are triggered by H 2 O 2 derived from complexes I and III
in the endothelial electron transport chain [ 124 –130 ]. In addition,
graded production of H 2 O 2 by myocardial mitochondria serves as
a metabolic vasodilator to couple oxygen consumption to coronary
blood ﬂow by activation of redox- and 4-aminopyridine-sensitive
voltage-dependent potassium (Kv) channels and has also been im-
plicated in the regulation of coronary collateral ﬂow [ 131 –133 ]. 
Recent work has established that mitochondrially centered mech-
anisms play an important role in promoting the activation of cell sur-
vival programs mediating preconditioning via mechanisms that in-
volve ROS signaling ( Fig. 3 ). Preconditioning refers to a phenomenon
where transient exposure of cells, tissues, or organs to a sublethal
stress (such as short bouts of ischemia prior to or at the onset of
reperfusion, or ischemic pre- or postconditioning, respectively) or a
variety of pharmacologic agents (e.g., ethanol, KATP and BKCa channel
activators) enhances tolerance to potentially lethal I / R. Mitochondrial
speciﬁc targets include respiratory chain enzyme complexes, oxida-
tive phosphorylation, and KATP and BKCa channels localized on the
inner mitochondrial membrane. For example, NOX-derived oxidants
play a role in stroke, which can be prevented by antecedent exposure
to ethanol or grape polyphenol extracts [ 134 –136 ]. Moreover, ROS
production by the respiratory chain has been shown to activate mi-
tochondrial ATP-sensitive potassium channels (mKATP) [ 137 ], which
play a role in protection against stroke-induced damage in the brain
[ 137 –143 ]. When activated by preconditioning stimuli, these mKATP
channels allow potassium to ﬂow into mitochondria to produce de-
polarization and alkalinization of the mitochondrial matrix, which in
turn appears to activate cell survival signaling in both acute (early)
and late preconditioning in MI and stroke by inducing downstream
ROS production [ 138 , 144 , 145 ]. While ROS scavenging and mKATP
channel inhibitors reduce the cardioprotection afforded by ischemic
pre- and postconditioning or that induced by the mitoKATP opener
diazoxide, exogenous generation of ROS at the onset of reperfusion
fails to confer protection [ 146 ]. These latter results suggest that the
type of ROS, their concentration, and / or compartmental localization
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cf their production is critical to triggering tolerance to I / R, consis- 
ent with a mitochondrial site as a source for ROS generation that 
recipitates preconditioning. 
Abundant evidence supports a role for PKG- and Akt-dependent 
hosphorylation in the opening of mitoKATP and subsequent ROS 
ormation secondary to matrix alkalinization in pharmacologic pre- 
onditioning. According to this scenario, acetylcholine- or bradykinin- 
nduced PKG activation results in phosphorylation of a protein on the 
uter mitochondrial membrane which is coupled to mKATP activa- 
ion on the inner mitochondrial membrane by a step that involves 
KC- activation. ROS generation secondary to mitoKATP channel ac- 
ivation then activates a second pool of PKC which inhibits opening 
f the mitochondrial permeability transition pore (MPTP) to prevent 
ell death [ 145 , 147 –149 ]. 
The demonstration that preconditioning with diazoxide, a mi- 
oKATP activator, invoked protection against subsequent I / R-induced 
euronal injury and death provided some of the ﬁrst evidence that 
itoKATP channels participate in activation of cell survival programs 
n stroke [ 150 ]. This agent causes generation of ROS at low levels by 
echanism which may be related to its ability to inhibit complexes 
 and III of the electron transport chain to provoke precondition- 
ng [ 151 –157 ]. Others have presented evidence that mitochondrial 
onnexin-43 (Cx43) plays an important role in mKATP-dependent 
xidant signaling invoked by pharmacologic preconditioning with di- 
zoxide, bradykinin or acetylcholine in the heart [ 147 , 155 , 158 –160 ]. 
itochondrial oxidant production is also induced by preconditioning 
ith a δ-opioid agonist or endothelin-1. However, Cx43 knockdown 
id not affect ROS production by mitochondria induced by these pre- 
onditioning stimuli, but did abolish downstream cardioprotective 
ignaling events [ 161 ]. 
ROS production has also been shown to enhance mitoKATP chan- 
el activation and thus enhance mitochondrial membrane depolar- 
zation and confer preconditioning [ 156 , 157 ]. While these observa- 
ions clearly indicate that ROS signaling can activate mitoKATP to 
nhance preconditioning, treatment with BMS-191095, which acti- 
ates mitoKATP but does not increase mitochondrial ROS production, 
lso effectively reduces cerebral I / R injury [ 138 ]. The latter results 
ndicate that mitoKATP channel activation, independent of ROS pro- 
uction, can invoke tolerance to lethal I / R. However, it is important 
o note that when the electron transport chain is inhibited, as occurs 
n I / R, superoxide can interact with NO to produce peroxynitrite. 
he reactive nitrogen species potently activates mKATP and may trig- 
er preconditioning induced by short bouts of ischemia [ 138 ]. More- 
ver, respiratory chain inhibition results in decreased ATP production, 
hereby increasing the ADP / ATP ratio, which favors mKATP channel 
pening and activation of cell survival mechanisms. 
The observation that drugs acting on mitoKATP channels can trig- 
er oxidant-dependent cell survival signaling that limits I / R injury 
uggests the possibility that pharmacologic agents or interventions 
argeting other mitochondrial potassium channels could also elicit 
reconditioning. Indeed, it is well-established that activation of large 
onductance, calcium-activated potassium channels (BKCa), either by 
harmacologic agents or secondary to ischemic preconditioning, elicit 
olerance to prolonged I / R [ 162 –169 ]. Recent work indicates that 
reatment with the BKCa channel activator NS-1619 protected mito- 
hondrial function in cardiac I / R by a mechanism mediated by super- 
xide generation [ 167 ] but is independent of NO production [ 165 ]. 
n one study [ 167 ], it was assumed that BKCa channels localized on 
he inner mitochondrial membrane were responsible for superoxide 
eneration because NS-1619 treatment was dependent on superoxide 
roduction and was associated with reduced mitochondrial calcium 
ccumulation and improved redox state (i.e., normalized NADH) in 
 / R. In a subsequent study, the same group directly demonstrated 
hat NS-1619 increases mitochondrial oxidant production that was 
riven by increased mitochondrial matrix potassium secondary to 
hannel opening [ 170 ]. This in turn elevated matrix H + by enhanced but submaximal K + / H + exchange, thereby stabilizing mitochondrial 
membrane potential despite increased respiration. These conditions 
allowed increased direct electron transfer to oxygen thereby gener- 
ating superoxide [ 170 ]. 
Activation of uncoupling proteins, which reduces oxidative stress, 
has been reported to elicit cardioprotection in I / R [ 171 –175 ]. It is 
of interest to note that transient inhibition of complex I at reperfu- 
sion also exerts cardioprotective effects via reduced ROS production 
[ 176 , 177 ]. These observations suggest that postconditioning-induced 
tolerance to prolonged I / R would not be triggered by mild ROS pro- 
duction during staccato reperfusion. However, ROS have been shown 
to be important initiators of this form of conditioning [ 178 ]. Res- 
olution of these discrepant observations may simply relate to the 
concentration and / or site of ROS generation. 
A key event underlying preconditioning or postconditioning may 
be prolongation of cellular acidosis during early reperfusion after in- 
dex ischemia. It is thought that delayed normalization of pH acts to 
inhibit mPTP opening in the initial minutes of reperfusion, thereby 
allowing time for ROS-induced activation of cell survival programs. 
The ROS formed in the early minutes of acidic reperfusion or during 
the short bouts of intermittent reperfusion during postconditioning 
activates PKC-  isoforms, critical kinases in the signaling cascade that 
act to reduce the probability of mPTP opening after pH normalizes 
as reperfusion progresses [ 179 , 180 ]. In contrast, transient opening of 
the mPTP may also induce modest and short-lived ROS production 
that precipitates preconditioning, a concept supported by the obser- 
vations that antioxidant treatment during bouts of preconditioning 
I / R and pharmacologic inhibition or genetic ablation of cyclophilin 
D attenuates both preconditioning induced oxidant production and 
protection [ 181 –187 ]. 
Summary and perspectives 
From the aforementioned discussion, it appears the mitochondrial 
ROS generation plays a critical role in the pathogenesis of myocardial 
infarction and stroke. Although complexes I and III of the electron 
transport chain are the best studied sources of mitochondrial ROS gen- 
eration in I / R and may be responsible for much of the oxidative stress 
exhibited by postischemic cells, recent evidence indicates that deg- 
lutathionylated complex II and phosphorylated complex IV are also 
important sources for ROS formation in I / R. As discussed by Chen and 
Zweier [ 11 ], identiﬁcation of speciﬁc redox domains in the respiratory 
chain supercomplexes that are involved in overexuberant ROS gener- 
ation in mitochondria during ischemia and reperfusion, how oxidant- 
and nitrosative-dependent post-translational modiﬁcations at spe- 
ciﬁc sites may exacerbate ROS production (ROS-induced ROS release) 
in animal models of I / R, and how electron transport chain driven 
superoxide production provokes aconitase to produce hydroxyl rad- 
icals are important areas for future investigation. Postischemic ROS 
generation via the electron transport chain may also enhance oxida- 
tive stress via mitochondrial ROS-induced ROS release that may also 
involve induction of hydroxyl radical formation by the Krebs cycle 
enzyme aconitase and activation of Nox4. I / R can also be associated 
with an overabundance of circulating / tissue monoamines, which in 
turn fuels H 2 O 2 production by monoamine oxidase. The growth factor 
adaptor Shc (p66 Shc ) is a novel pathway of ROS production in I / R but 
evaluation of its contribution to postischemic tissue injury has only 
just begun. 
Despite the preponderance of evidence supporting a role for mi- 
tochondria as an intracellular source of ROS in the pathogenesis of I / 
R injury, recent work demonstrating that directed sarcolemmal sta- 
bilization uncouples increased oxidative stress from cellular dam- 
age and stress challenges this paradigm and provides an attractive 
explanation for the failure of anti-oxidant therapies to limit postis- 
chemic tissue injury. In an elegant series of experiments Martindale 
T. Kalogeris et al. / Redox Biology 2 (2014) 702–714 709 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 and Metzer [ 188 ] demonstrated that reperfusion produced intracel-
lular oxidative stress and lipid peroxidation, membrane instability
and swelling, which in turn induced Ca 2 + inﬂux and mitochondrial
membrane depolarization. Directed stabilization of the outer mem-
brane with synthetic copolymers consisting of tandem linear arrays
of polyethylene oxide / polypropylene oxide moieties reduced postis-
chemic necrosis, apoptosis, hypercontracture and mitochondrial dys-
function without disrupting intracellular oxidative stress or lipid per-
oxidation. Moreover, these investigators further demonstrated that
dystrophin deﬁciency (which increases fragility of cardiac and other
cell membranes and is associated with increased oxidative stress)
[ 189 –193 ], increased susceptibility to myocardial I / R, an effect that
was mitigated by copolymer treatment, while restoration of mem-
brane dystrophin contributeds to the cardioprotective effects of is-
chemic preconditioning [ 190 , 194 ]. Taken together, these observa-
tions suggest that I / R-induced, oxidant-mediated lipid peroxidation
was insufﬁcient by itself to induce cardiac injury and cell death when
sarcolemmal membrane integrity was maintained, suggesting that
ROS production is not the major factor responsible for the Ca 2 + dys-
regulation that ultimately results in cell death in postischemic my-
ocardium. Rather, it appears that sarcolemmal compromise, which
limits its ability to maintain a barrier between the intra- and extra-
cellular compartments, may be the decisive irreversible event that
leads to cell death in I / R. 
Since the copolymers do not exhibit free radical scavenging capac-
ity and are restricted to engaging the sarcolemmal surface by their
amphiphilic structure [ 69 ], these studies challenge the paradigm that
intracellular oxidant generation from sources such as mitochondria
play the decisive role in the pathogenesis of I / R injury. However, it
is possible that oxidants generated from intracellular sources such as
mitochondria may target the extracellular face of sarcolemmal mem-
brane after transmembrane egress via anion channels. Membrane
packing or altered mobility induced by copolymer binding could limit
diffusion of oxidant species into the bilayer, providing an alternate
mechanistic rationale to reconcile a role for intracellular oxidant gen-
eration, membrane fragility, and cell death. Alternatively, stabiliza-
tion of the outer cell membrane may alter cytoskeletal interactions
which in turn may modify or disrupt mitochondrial trafﬁcking such
that these organelles are directed away from intracellular sites such
as the nucleus that are particularly vulnerable to ROS attack, thereby
allowing elevated intracellular ROS production to persist but limiting
its intracellular consequences. The effectiveness of mitochondrially-
targeted antioxidant treatments, which presumably do not act via
membrane stabilization, in reducing I / R injury in preclinical I / R mod-
els appear to support important roles for mitochondrial ROS as a de-
cisive contributor to postischemic injury, suggesting that alternate
explanations for the protective effects afforded by copolymer treat-
ment should be explored. 
While it seems clear that overexuberant ROS production by mi-
tochondria may contribute to I / R, it is also appears that production
of hydrogen peroxide by this organelle serves as an important sig-
naling element that couples cellular metabolism to blood ﬂow and
as a mediator of ﬂow-dependent vasodilation in the coronary circu-
lation. Mitochondrial ROS generation also appears to play a critical
role in evoking the expression of cell survival programs that miti-
gate postischemic tissue injury and cell death by a variety of pre-
and postconditioning stimuli. The cardioprotective mechanisms in-
duced by preconditioning clearly involve activation of mitochondrial
KATP and BKCa channels, which produce membrane alkalinization
and ROS generation by respiratory chain supercomplexes, which in
turn activate downstream signaling elements to induce expression of
cardioprotective proteins that limit I / R injury and cell death. Thus,
production of ROS by mitochondria can exert counterbalancing ef-
fects on tissue cells, with a low ﬂux of mitochondrial oxidants serving
signaling functions to regulate vascular caliber to meet metabolic de-
mands. In addition, mitochondrial ROS production at signaling levelsand perhaps localized at speciﬁc subcellular sites within mitochon-
dria or other organelles activate cell survival programs to enhance
tolerance to ischemia. On the other hand, overproduction of mito-
chondrial oxidants leads to ROS-induced ROS release to exacerbate
oxidative stress that promotes mitochondrial permeability transition,
which in turn precipitates swelling that can progress to cell lysis and
death during I / R. 
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